[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrence-free\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrence-free":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100659996","long-term-quality-of-life-and-symptom-assessment-among-recurrence-free-patients-who-underwent-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-100659996",false,"NCT07871760","Long-Term Quality Of Life And Symptom Assessment Among Recurrence-Free Patients Who Underwent Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","Inclusion Criteria:\n\n1. Males and females; age ≥18 years at the time of enrollment\n2. Underwent curative-intent CRS\u002FHIPEC at MD Anderson for gastrointestinal malignancies, including colorectal cancers, appendiceal cancers, and peritoneal mesothelioma between March 1, 2016, and June 30, 2025\n3. Had a complete cytoreduction with a completeness of cytoreduction score (CC) of 0 or 1\n4. Currently alive and at least 6 months disease-free post-CRS\u002FHIPEC, based on clinical documentation and follow-up imaging\n5. English-speaking\n6. Capable of completing an electronic survey (via REDCap)\n7. Provides informed consent by proceeding to survey commencement\n\nExclusion Criteria:\n\n* 1\\. Evidence of recurrent or active malignancy at time of chart review 2. Underwent CRS\u002FHIPEC for non-malignant conditions (e.g., multicystic mesothelioma, well-differentiated papillary mesothelioma) 3. Underwent palliative-intent surgery or had an incomplete cytoreduction (CC-2 or CC-3) 4. Did not receive HIPEC (CRS only) 5. Received HIPEC on a clinical trial 6. Significant cognitive impairment limiting ability to provide informed consent or complete the survey 7. Non-English-speaking (due to lack of validated translations for study instruments) 8. No valid contact information or no access to electronic communication (e.g., participant portal or email)","ALL","18 Years",{"count":18,"type":19},300,"ESTIMATED","OBSERVATIONAL","To evaluate long-term quality of life (QoL) and participant reported symptom burden in disease-free survivors who have undergone cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS\u002FHIPEC) at MD Anderson, with primary emphasis on overall (composite) QoL as measured by validated instruments.",[23,24,25,26,27],"Long Term","Quality of Life","Recurrence Free","Cytoreductive Surgery","Hyperthermic Intraperitoneal Chemotherapy","NOT_YET_RECRUITING","2026-10-08",{"date":31,"type":32},"2026-10-13","ACTUAL",{"date":34,"type":19},"2027-03-22",{"date":36,"type":19},"2028-12-31",{"name":38,"class":39},"M.D. Anderson Cancer Center","OTHER"]